Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
View/Open
Author
Ortega, Natalia 
Ribes, Marta
Rubio Bodí, Rocío
Aguilar, Ruth
Alonso, Selena
Hernández-Luis, Pablo
Mitchell, Robert
Cruz Vazquez, Angeline Marie
JIMENEZ, ALFONS
Santano García, Rebeca
Méndez, Susana
Lamoglia Puig, Montserrat
Llupià, Anna
Chi, Jordi
Pradenas, Edwards
Blanco, Julià
Mayor Aparicio, Alfredo Gabriel
Trilla, Antoni
Carolis, Carlo
Izquierdo, Luis
Garcia-Basteiro, Alberto L.
Moncunill, Gemma
Dobaño Lazaro, Carlota
Publication date
2021Abstract
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). [...]
Document Type
Article
Citation
Ortega N, Ribes M, Vidal M, Rubio Bodí R, Aguilar R, Williams S, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021;12(1):4740. DOI: 10.1038/s41467-021-24979-9
This item appears in the following Collection(s)
- Articles [52]
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
